Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
RMD Open. 2025;11:e005026. doi: 10.1136/rmdopen-2024-005026.
Mease et al. found that bimekizumab demonstrated a favourable long-term safety profile in patients with axSpA and PsA.
The study pooled safety data from six integrated phase IIb/III clinical trials involving adult patients with axSpA and PsA, focusing on those who received at least one dose of bimekizumab 160 mg every four weeks, with the primary aim of assessing the long-term safety profile and incidence of TEAEs over an extended treatment period.
